The process of care model for evaluation and treatment of erectile dysfunction

International Journal of Impotence Research

Volumn 11, Issue 2, 1999, Pages 59-74

  Rosen, Raymond C ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; PROSTAGLANDIN E1; SILDENAFIL;

ADULT; AGED; ALGORITHM; ARTICLE; ERECTILE DYSFUNCTION; EVIDENCE BASED MEDICINE; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTHESIS; QUALITY OF LIFE; RISK FACTOR; SEXUAL DYSFUNCTION; TREATMENT OUTCOME; VACUUM CONSTRICTION DEVICE;

EID: 0033044322     PISSN: 09559930     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ijir.3900411     Document Type: Article

References (62)

1. NIH Consensus Panel on Impotence. Impotence. JAMA 1993; 270: 83-90.
2. Feldman HA et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54-61.
3. Laumann EO, Gagnon JH, Michael RT, Michaels S. The social organization of sexuality: Sexuality practices in the United States. Chicago: University of Chicago Press, 1994.
4. Goldstein I et al. Radiation-associated impotence. A clinical study of its mechanism. JAMA 1984; 251: 903-910.
5. Quinlan DM, Epstein JI, Carter BS, Walsh PC. Sexual function following radical prostatectomy: Influence of preservation of neurovascular bundles. J Urol 1991; 145: 998-1002.
6. Courtois FJ, McDougall JC, Sachs BD. Erectile mechanisms in paraplegia. Physiol Behav 1993; 53: 721-726.
7. Araujo AB et al. The relationship between depressive symptoms and male erectile dysfunction: Cross-sectional results from the Massachusetts Male Aging Study. Psychosomatic Medicine 1998; 60: 458-465.
8. Korenman SG et al. Secondary hypogonadism in older men: Its relationship to impotence. J Clin Endocrinol Metab 1990; 71: 963-969.
9. Schiavi R. Sexuality and aging in men. Ann Rev Sex Res 1990; 1: 227-250.
10. Zonszein J. Diagnosis and management of endocrine disorders of erectile dysfunction. Urol Clin No Amer 1995; 22: 789-802.
11. Rajfer J et al. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med 1992; 326: 90-94.
12. Andersson KE, Wagner G. Physiology of penile erection. Physiol Rev 1995; 75: 191-236.
13. Kim N, Azadzoi KM, Goldstein I, Saenz de Tejada I. A nitric-oxide like factor mediates non-adrenergic non-cholinergic neurogenic relaxation of penile corpus cavernosum smooth muscle. J Clin Invest 1991; 88: 112-118.
14. Taub HC, Lerner SE, Melman A, Christ GJ. Relationship between contraction and relaxation in human and rabbit corpus cavernosum. Urology 1993; 42: 698-704.
15. Burnett A. Nitric oxide in the penis: physiology and pathology. J Urol 1997; 157: 320-324.
16. McKenna KE. Central control of penile erection. Int J Impot Res 1998; 10: S25-S34.
17. Boolel M, Gepi-Attee S, Gingell JC, Allen MJ. Sildenafil, a novel effective oral therapy for male erectile dysfunction. Br J Urol 1996; 78: 257-261.
18. Goldstein I et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998; 338: 1397-1404.
19. Kahan KL et al. Measuring the clinical appropriateness of a procedure: Can we do it? Medical Care 1988; 26: 415-422.
20. Brook RH et al. A method for the detailed assessment of the appropriateness of medical technologies. Int J Technol Assess Health Care 1986; 2: 53-63.
21. Burnett AL. Erectile dysfunction. A practical approach for primary care. Geriatrics 1998; 53: 34-48.
22. Davis-Joseph B, Tiefer L, Melman A. Accuracy of the initial history and physical examination to establish the etiology of erectile dysfunction. Urology 1995; 45: 498-502.
23. Citron JT et al. Prevalence of hypothalamic-pituitary imaging abnormalities in impotent men with secondary hypogonadism. J Urol 1996; 155: 529-533.
24. Johnson AR, Jarow JP. Is routine endocrine testing of impotent men necessary? J Urol 1992; 147: 1542-1544.
25. Carter HB, Epstein JI, Walsh PC, Parton AW. Age, PSA and the chance of curable prostate cancer among men with non-palpable disease. J Urol 1998; 159: 74.
26. Albertson PC. Urological "nuisances": how to work up and relieve men's symptoms. Geriatrics 1997; 52: 46-60.
27. Burnap DW, Golden JS. Sexual problems in medical practice. J Med Educ 1967; 42: 673-686.
28. Leiblum SR et al. Sexual attitudes and behavior of a cross-sectional sample of U.S. medical students: Effects of gender, age and year of study. J Sex Educ Therapy 1993; 19: 235-245.
29. Meuleman EJ, Diemont WL. Investigation of erectile dysfunction: Diagnostic testing for vascular factors in erectile dysfunction. Urol Clin No Amer 1995; 22: 803-819.
30. Kaufman JM et al. Evaluation of erectile dysfunction by dynamic infusion cavernosometry and cavernosography (DICC). Urology 1993; 41: 445-451.
31. Levine LA, Lenting EL. Use of nocturnal penile tumescence and rigidity in the evaluation of male erectile dysfunction. Urologic Clinic of No Am 1995; 22: 775-788.
32. Bemelmans BL et al. Comparison of biothesiometry and neurophysiological investigations for the clinical evaluation of patients with erectile dysfunction. J Urol 1995: 153: 1483-1486.
33. Rosen RC. Alcohol and drug effects on sexual response: Human experimental and clinical studies. Annual Review of Sex Research 1991; 2: 119-180.
34. Grimm R et al. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women in the Treatment of Mild Hypertension Study (TOHMS). Hypertension 1997; 29: 8-14.
35. Wassertheil-Smoller S et al. Effects of antihypertensives on sexual function and quality of life: The TAIM Study. Ann Intern Med 1991; 114: 613-620.
36. Gupta S et al. Digoxin enhances corpus cavernosum smooth muscle contractility by inhibition of Na-K-ATPase activity: A new mechanism for digoxin-associated alteration of human erectile function. J Urol 1998; 159: 1529-1536.
37. Harrison WM et al. Effects of antidepressants on sexual function: A controlled study. J Clin Psychopharm 1985; 6: 144-149.
38. Rosen RC, Menza M, Lane R. Effects of SSRI's on sexual function: A critical review. J Clin Psychopharm 1999; 19: 67-85
39. Zonszein J. Diagnosis and management of endocrine disorders of erectile dysfunction. Urol Clin No Amer 1995: 22: 789-802.
40. Lund GO, Winfield HN, Donovan JF. Laparoscopically assisted penile revascularization for vasculogenic impotence. J Urol 1995; 153: 1923-1926.
41. Jarow JP, DeFranzo AJ. Long-term results of arterial bypass surgery for impotence secondary to segmental vascular disease. J Urol 1996; 156: 982-985.
42. Gwinup G. Oral phentolamine in nonspecific erectile insufficiency. Ann Intern Med 1988; 109: 162-163.
43. Heaton JPW et al. Recovery of erectile function by the oral administration of apomorphine. Urology 1995; 45: 200-206.
44. ACC/AHA Expert Consensus Document: Use of silclenafil in patients with cardiovascular disease. Circulation 1999; 99: 168-177.
45. Lewis RW, Witherington R. External vacuum therapy for erectile dysfunction: use and results. World J Urol 1997; 15: 78-82.
46. Korenman SG, Viosca SP. Use of a vacuum tumescence device in the management of impotence in men with a history of penile implant or severe pelvic disease. J Amer Geriatr Soc 1992; 40: 61-64.
47. Rosen RC, Leiblum SR, Spector IP. Psychology based treatment for male erectile disorder: A cognitive-interpersonal model. J of Sex & Mar Ther 1994; 20: 67-83.
48. Hawton K. Integration of treatments for male erectile dysfunction. Lancet 1998; 351: 7-8.
49. Heiman JR. Meston CM. Empirically validated treatment for sexual dysfunction. Annual Rev Sex Res 1997; 7: 148-194.
50. Padma-Nathan H et al. Treatment of men with erectile dysfunction with transurethral alprostadil. N Engl J Med 1997; 336: 1-7.
51. Spivak AP et al. Long-term safety profile of transurethral alprostadil for the treatment of erectile dysfunction. J Urol 1997; 157: 792A.
52. Fulgham PF et al. Disappointing results with transurethral alprostadil in men with erectile dysfunction (erectile dysfunction) in a urology practice setting. J Urol 1998; 159: 237.
53. Linet OI, Ogrinc FG, for the Alprostadil Study Group. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. N Engl J Med 1996; 334: 873-877.
54. Fallon B. Intracavernous injection therapy for male erectile dysfunction. Urol Clin N Am 1995; 22: 833-845.
55. Lewis RW. Long-term results of penile prosthetic implants. Urologic Clinics of No Am 1995; 22: 847-856.
56. Pedersen B et al. Evaluation of patients and partners 1 to 4 years after penile prosthesis surgery. J Urol 1988; 139: 956-958.
57. 1 suppresses the induction of collagen synthesis by transforming growth factor beta-1 in human corpus cavernosum smooth muscle. J Urol 1995; 153: 826-834.
58. Rosen RC. Sexual dysfunction as an obstacle to compliance with antihypertensive therapy. Blood Pressure 1997; 6: S47-51.
59. Christ GJ, Melman A. The application of gene therapy to the treatment of erectile dysfunction. Int J Impot Res 1998; 10: 111-112.
60. Leiblum SR, Rosen RC. Couples therapy for erectile disorders: Observations, obstacles and outcomes. In: Rosen RC, Leiblum SR. eds. Erectile disorders: Assessment and treatment. New York: Guilford Press, 1992 (pp 226-254).
61. Hawton K, Catalan J, Fagg J. Sex therapy for erectile dysfunction: Characteristics of couples, treatment outcome and prognostic factors. Arch Sex Behav 1992; 21: 161-176.
62. Goldstein I, Berman J. Vasculogenic female sexual dysfunction: Vaginal engorgement and clitoral erectile insufficiency syndrome. Int J Impot Res 1998; 10: S84-S90.